Questions about GIA®

GIA® — the AI Co-Clinician Digital Human® from Scienza Health — initiates a short, structured natural conversation with a patient by video, voice, or landline. During the 40-second interaction, she analyzes 2,500+ speech biomarkers and visual signals, screening for 46 cognitive, neurological, and behavioral conditions simultaneously. Results, transcripts, and clinician-ready notes are delivered to the EHR in under 2 minutes. No staff time is required during the screening, and the clinician reviews and approves every result before it enters the clinical record.

GIA® is an AI Co-Clinician Digital Human® designed to support clinical teams across the full care continuum. In outpatient settings, primary care physicians, neurologists, geriatricians, and psychiatrists use GIA® to screen patients before or between visits — walking into appointments with objective data already in the EHR. In post-acute and long-term care, the operational care team — Medical Directors, Directors of Nursing, and Administrators — relies on GIA® for consistent screening, BIMS / ADL / IADL administration, and structured documentation. For multi-facility and SNF operators, GIA® delivers a standardized layer of clinical intelligence across an entire portfolio. GIA® is built by Scienza Health, a clinical intelligence company founded in 2024 in Newport Beach, California.

Yes. GIA® by Scienza Health administers the Brief Interview for Mental Status (BIMS) interview during the patient interaction and writes structured results to the EHR. CMS requires BIMS for every skilled nursing facility resident under MDS 3.0 Section C — on admission, quarterly, and on significant change. Clinicians review and approve all results before they enter the clinical record.

GIA® by Scienza Health administers the standardized BIMS interview as part of the natural patient conversation. Results are structured into medical notes and written back to the EHR. The clinician reviews and approves the BIMS score before it enters the clinical record. GIA® captures the data and supports clinical judgment — it does not score or interpret BIMS independently.

GIA® by Scienza Health administers the Barthel Index and Katz Index of Independence — both validated ADL assessment instruments. Results are structured into medical notes and written back to the EHR for clinician review and approval. ADL administration is separate from GIA®'s 46-condition biomarker screening — both capabilities complete within a single patient interaction.

ADL (Activities of Daily Living) covers basic self-care: bathing, dressing, toileting, transferring, and eating. IADL (Instrumental Activities of Daily Living) covers higher-order tasks: managing finances, medication management, transportation, and meal preparation. GIA® by Scienza Health administers ADL instruments (Barthel Index, Katz Index) and IADL instruments (Lawton Scale, Functional Independence Measure) — all with EHR write-back and clinician review.

GIA® by Scienza Health administers BIMS (MDS 3.0 Section C) and ADL and IADL assessment instruments, with structured results written back to the EHR. This supports MDS 3.0 documentation for cognitive status and functional ability. Clinicians review and approve all results before they enter the clinical record. GIA® supports MDS documentation — it does not replace clinical judgment.

No. GIA® by Scienza Health supports clinical judgment — it does not replace it. GIA® screens through speech biomarker analysis and administers structured assessment instruments, but every result is reviewed and approved by a clinician before it enters the clinical record. No clinical action is taken without clinician review.

GIA® by Scienza Health screens for 46 cognitive, neurological, and behavioral conditions from a single 40-second natural conversation — including cognitive decline, mild cognitive impairment, Alzheimer's disease, Parkinson's disease, depression, anxiety, PTSD, and 39 additional conditions. Full condition list at scienzahealth.com/screening.

Yes. GIA® by Scienza Health is HIPAA compliant and SOC 2 Type II certified. Patient data is handled in accordance with HIPAA requirements, with AES-256 encryption at rest and TLS 1.3 in transit. The platform runs on Samsung Knox-secured Galaxy devices. All screening results require clinician review before entering the clinical record.

Speech biomarkers are acoustic and linguistic features extracted from natural conversation — including vocal rate, rhythm, pitch, pausing patterns, and word choice complexity. Research has shown these features correlate with cognitive, neurological, and behavioral conditions. GIA® by Scienza Health analyzes 2,500+ speech biomarkers during a 40-second patient interaction to identify early risk signals across 46 conditions. Results are delivered to the clinician's EHR in under 2 minutes. View peer-reviewed research at scienzahealth.com/research.

digitalhumanOS™ is the clinical intelligence operating system that powers GIA®. It processes Voice AI, Computer Vision, and Speech Biomarker analysis in real time during patient screening conversations. digitalhumanOS™ is the infrastructure — GIA® is the patient-facing digital human who conducts the screening.

GIA® integrates with PointClickCare, Epic, Cerner, MatrixCare, Netsmart, and American HealthTech through HL7 FHIR and Direct API connections. Four data types write back to the patient record automatically: structured screening results with ICD-10 codes, clinician-ready medical notes, a full timestamped transcript, and the recorded patient video.

Organizations deploy GIA® in under 30 minutes. She comes pre-bundled on Samsung Health Grade Galaxy devices with Samsung Knox security. No software procurement, no IT integration project, no compatibility testing. The device arrives ready.

GIA® runs on Samsung Health Grade Galaxy devices (tablets and smartphones) with Samsung Knox security, iOS devices, and any web-enabled device. Samsung DeX allows any Galaxy phone or tablet to function as a full workstation for nursing stations.

GIA® is peer-reviewed across 19 published studies by independent researchers at Beth Israel Deaconess Medical Center, NIH, MIT, Harvard Medical School, and The Lancet, with reported AUC values of 0.890 for cognitive decline, 0.97 for Parkinson's indicators, 0.816 for depression, 0.800 for PTSD, and 0.775 for anxiety. Independent peer-reviewed evidence is the appropriate standard for evaluating any AI screening tool.

Peer-reviewed accuracy includes Depression at AUC 0.816, PTSD at AUC 0.800, Anxiety at AUC 0.775, and Parkinson’s at AUC 0.97. These figures are validated through published clinical research. Scienza Health never fabricates or approximates accuracy claims.

digitalhumanOS™ is trained on 12.3 million longitudinal PAC/LTC patient records and 27 billion clinical events from clinical settings. This dataset is the largest of its kind purpose-built for PAC/LTC clinical screening.

No. GIA® operates within a 5-layer governance framework with mandatory human-in-the-loop review. She delivers screening results to the clinician in under 2 minutes. The clinician reviews and submits — no result enters the clinical record without human approval.

GIA® analyzes over 2,500 speech biomarkers per conversation, including vocal tremor, articulatory precision, prosodic patterns, and cognitive load indicators. During video sessions, she also captures 436 visual data points from facial micro-expressions and body movement.

GIA® screens for 46 conditions prevalent in SNFs, including cognitive impairment, MCI, Alzheimer’s disease, Parkinson’s disease, depression, PTSD, anxiety, bipolar disorder, sleep disorders, and substance abuse. The platform uses voice and speech biomarkers to detect subtle changes, enabling early identification and intervention.

Voice biomarker analysis offers an objective alternative to subjective questionnaires. It reduces staff and resident bias, captures subtle pre-symptomatic changes, and can be administered more frequently with less burden. This provides a more consistent and sensitive longitudinal view of cognitive and mental health.

Yes. GIA® detects pre-symptomatic indicators through vocal biomarker analysis. Changes in vocal prosody — reduced pitch variability, slower speech rate, altered pause patterns — can signify depressive states before a resident self-reports or displays overt symptoms, enabling proactive clinical assessment.

GIA® employs machine learning algorithms to analyze acoustic and linguistic features from speech. These voice biomarkers correlate with neuropathological changes associated with cognitive and mood disorders. The platform analyzes patterns in pitch, tone, rhythm, and word choice to generate an objective risk score.

Peer-reviewed validation shows AUC 0.816 for depression detection via voice biomarker analysis. The platform is peer-reviewed across 19 studies and trained on 12.3 million longitudinal PAC/LTC patient records. A clinician reviews every result before it enters the clinical record.

Zero staff time during screening. GIA® conducts the conversation independently via video, voice, or landline. A staff member initiates the screening on a tablet or device. The clinician reviews results in under 2 minutes. No trained screening staff required.

GIA® integrates natively with PointClickCare for real-time write-back of screening results, structured medical notes, full conversation transcripts, and recorded patient video. No manual data entry required. Scienza Health is a verified partner on the PointClickCare Marketplace.

Facilities see ROI through early detection of previously missed conditions (projected $180K–$240K in new CPT reimbursement for a 200-bed SNF), reduced rehospitalizations, recovered clinician hours, and improved CMS quality metrics. All projections modeled from published benchmarks.

Yes. GIA® provides objective screening data for cognition and mood that supports MDS 3.0 sections C1300 (cognitive function) and D0100–D0600 (mood). The quantitative evidence informs more accurate and defensible coding for PDPM classification.

GIA® documents every screening interaction with timestamped results, structured notes, and the full conversation record. This automated documentation supports psychotropic medication monitoring requirements under F-Tag 605, creating a defensible audit trail for CMS surveys.

GIA® is fully HIPAA compliant. All resident data is encrypted in transit and at rest using AES-256 encryption. The platform runs on Samsung Knox-secured devices and operates within a SOC 2-certified cloud infrastructure with strict access controls and regular security audits.

FDA device establishment registration with the FDA demonstrates that the device is substantially equivalent to a legally marketed predicate device. It validates the platform for clinical use in screening, distinguishing it from wellness apps and confirming it meets regulatory standards for safety and performance.

Accurate condition detection improves the clinical quality metrics that drive CMS star ratings. By identifying previously undetected cognitive and behavioral conditions, GIA® helps facilities improve screening rates, reduce rehospitalizations, and strengthen documentation — all factors in the five-star quality rating system.

GIA® screenings support CPT 96127 (brief behavioral assessment, $6–$11), CPT 96116 (neurobehavioral status exam, $94–$131), and CPT 99309 (subsequent nursing facility care, approximately $100). The platform documents the billable event and prepares CPT-coded results for clinician review.

GIA® screens for conditions that drive psychotropic prescribing — depression, anxiety, PTSD, bipolar disorder — and provides documented screening evidence. This supports gradual dose reduction protocols and F-Tag 605 requirements by ensuring behavioral health conditions are properly identified and monitored.